Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review

The field of precision medicine endeavors to transform the healthcare industry by advancing individualised strategies for diagnosis, treatment modalities, and predictive assessments. This is achieved by utilizing extensive multidimensional biological datasets encompassing diverse components, such as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EClinicalMedicine 2024-07, Vol.73, p.102660, Article 102660
Hauptverfasser: Singh, Manasvi, Kumar, Ashish, Khanna, Narendra N., Laird, John R., Nicolaides, Andrew, Faa, Gavino, Johri, Amer M., Mantella, Laura E., Fernandes, Jose Fernandes E., Teji, Jagjit S., Singh, Narpinder, Fouda, Mostafa M., Singh, Rajesh, Sharma, Aditya, Kitas, George, Rathore, Vijay, Singh, Inder M., Tadepalli, Kalyan, Al-Maini, Mustafa, Isenovic, Esma R., Chaturvedi, Seemant, Garg, Deepak, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Viswanathan, Vijay, Kalra, Manudeep K., Ruzsa, Zoltan, Saba, Luca, Laine, Andrew F., Bhatt, Deepak L., Suri, Jasjit S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The field of precision medicine endeavors to transform the healthcare industry by advancing individualised strategies for diagnosis, treatment modalities, and predictive assessments. This is achieved by utilizing extensive multidimensional biological datasets encompassing diverse components, such as an individual's genetic makeup, functional attributes, and environmental influences. Artificial intelligence (AI) systems, namely machine learning (ML) and deep learning (DL), have exhibited remarkable efficacy in predicting the potential occurrence of specific cancers and cardiovascular diseases (CVD). We conducted a comprehensive scoping review guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework. Our search strategy involved combining key terms related to CVD and AI using the Boolean operator AND. In August 2023, we conducted an extensive search across reputable scholarly databases including Google Scholar, PubMed, IEEE Xplore, ScienceDirect, Web of Science, and arXiv to gather relevant academic literature on personalised medicine for CVD. Subsequently, in January 2024, we extended our search to include internet search engines such as Google and various CVD websites. These searches were further updated in March 2024. Additionally, we reviewed the reference lists of the final selected research articles to identify any additional relevant literature. A total of 2307 records were identified during the process of conducting the study, consisting of 564 entries from external sites like arXiv and 1743 records found through database searching. After 430 duplicate articles were eliminated, 1877 items that remained were screened for relevancy. In this stage, 1241 articles remained for additional review after 158 irrelevant articles and 478 articles with insufficient data were removed. 355 articles were eliminated for being inaccessible, 726 for being written in a language other than English, and 281 for not having undergone peer review. Consequently, 121 studies were deemed suitable for inclusion in the qualitative synthesis. At the intersection of CVD, AI, and precision medicine, we found important scientific findings in our scoping review. Intricate pattern extraction from large, complicated genetic datasets is a skill that AI algorithms excel at, allowing for accurate disease diagnosis and CVD risk prediction. Furthermore, these investigations have uncovered unique genetic biomarkers linked to CVD, providing insight i
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2024.102660